Hanmi Pharm's Diabetes Treatment Efpeglenatide Receives Phase 3 IND Approval
Hanmi Pharm announced on January 21 that it has received approval from the Ministry of Food and Drug Safety for a domestic Phase 3 clinical trial plan (IND) for the development of 'HM11260C' (efpeglenatide), a treatment for type 2 diabetes.
This clinical trial is designed to confirm the efficacy and safety of HM11260C in patients with type 2 diabetes whose condition is not controlled by metformin and dapagliflozin.
The purpose of the trial is to demonstrate the superiority of HM11260C in blood glucose control compared to placebo when administered in combination, and to comparatively assess its safety.
The trial will be conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel-design study involving 118 domestic patients.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hanmi Pharm stated in its announcement, "Through this clinical trial, we aim to develop HM11260C as a blood glucose control treatment for patients with type 2 diabetes."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.